A knowledge of the fate of a drug, its disposition (absorption, distribution, metabolism, and excretion, known by the acronym ADME) and pharmacokinetics (the mathematical description of the rates of these processes and of concentration-time relationships), plays a central role throughout pharmaceutical research and development. These studies aid in the discovery and selection of new chemical entities, support safety assessment, and are critical in defining conditions for safe and effective use in patients. ADME studies provide the only basis for critical judgments from situations where the behavior of the drug is understood to those where it is unknown: this is most important in bridging from animal studies to the human situation. This presentation is intended to provide an introductory overview of the life cycle of a drug in the animal body and indicates the significance of such information for a full understanding of mechanisms of action and toxicity.
Alden CL, Kanerva RC, Ridder G., and Stone LC (1983). The pathogenesis of the nephrotoxicity of volatile hydrocarbons in the male rat. In: Proceedings of the Workshop on the Kidney Effects of Hydrocarbons. American Petroleum Institute, Washington, D.C., pp. 186-193.
2.
Benet LZ (1978). Effect of route of administration and tissue distribution on drug action. J. Pharmacokinet. Biopharm. 6: 559-585.
3.
Benet LZ, Mitchell JR, and Sheiner LB (1990). Pharmacokinetics : The dynamics of drug absorption, distribution and elimination. In: The Pharmacological Basis of Therapeutics, A Goodman Gilman, TW Rall, AS Nies , and P Taylor (eds). Pergamon Press, Oxford, pp. 1-32.
4.
Benet LZ and Sheiner LB (1985). Pharmacokinetics: The dynamics of drug absorption distribution and elimination. In: The Pharmacological Basis of Therapeutics, AG Gilman, LS Goodman, TW Ball, and F Mirac (eds). Macmillan , New York, pp. 3-34.
5.
Berk PDPotter BJ, and Stremmel W. (1987). Role of plasma membrane ligand binding proteins in the hepatocellular uptake of albumin bound anions. Hepatology7 : 165-176.
6.
Boberg EW, Miller EC, Miller JA, Poland A., and Liem A. (1983). Strong evidence from studies with brachymorphic mice and pentachlorophenol that 1'-sulfooxysafrole is the major ultimate electrophilic and carcinogenic metabolite of 1'-hydroxysafrole in mouse liver. Cancer Res. 43: 5163-5173.
7.
Brodie BB (1964). Physicochemical factors in drug absorption. In: Absorption and Distribution of Drugs, TB Binns (ed). Williams and Wilkin, Baltimore, Maryland, pp. 16-48.
8.
Burchell B. and Coughtrie MWH (1992). UDP-glucuronosyltransferases . In: Pharmacogenetics of Drug Metabolism, W Kalow (ed). Pergamon Press, New York, pp. 195-225.
9.
Calabrese EJ (1985). Toxic Susceptibilities - Malel Female Differences . John Wiley & Sons, New York, Chichester.
10.
Caldwell J. (1980). Comparative aspects of detoxication in mammals . In: Enzymatic Basis of Detoxication, W Jakoby (ed). Academic Press, New York. pp. 85-114.
11.
Caldwell J. (1986). Conjugation mechanisms of xenobiotic metabolism mammalian aspects. In: Xenobiotic Conjugation Chemistry, GA Paulson, J Caldwell, DH Hutson, and JJ Menn (eds). American Chemical Society, Washington, D.C., pp. 2-28.
12.
Caldwell J. (1988). Xenobiotic metabolism-An introduction. In: Intermediary Xenobiotic Metabolism, DH Hutson, J Caldwell, and GA Paulson (eds). Taylor & Francis , London, pp. 3-12.
13.
Caldwell J. (1993). Biochemical basis of toxicity. In: General and Applied Toxicity, BC Ballantyne , T Marrs, and P Turner (eds). MacMillan, London, pp. 165-178.
14.
Caldwell J. , Howes AJ, and Hotchkiss SA (1990). The toxicological significance of xenobiotic metabolism. Fd. Add. Contam. 7: 116-126.
15.
Caldwell J., Weil A., and Tanaka Y. (1989). Species differences in xenobiotic conjugation . In: Xenobiotic Metabolism and Disposition, R Kalow, RW Estabrook , and MN Cayen (eds). Taylor & Francis, London, pp. 217-224.
16.
Dahlin DC, Miwa GT, Lu AYH, and Nelson SD (1984). N-acetyl-p-benzoquinimine. A cytochrome P450 mediated oxidation product of acetaminophen. Proc. Natl. Acad. Sci. USA81: 1327-1331.
17.
Eichelbaum M. and Gross AS (1992). The genetic polymorphism of debrisoquine/sparteine metabolism-Clinical aspects. In Pharmacogenetics of Drug Metabolism, W Kalow (ed). Pergamon Press, Oxford, pp. 625-648.
18.
Falany CN (1991). Molecular enzymology of human liver cytosolic sulfotransferases. Trends Pharmacol. Sci. 12: 255-259.
19.
Feron VJ and Kroes R. (1986). The long-term study in rodents for identifying carcinogens. Some controversies and suggestions for improvements. J. Appl. Toxicol. 6: 307-311.
20.
Flamm WG and Lehmann-McKeeman LD (1991). The human relevance of the renal tumour-inducing potential of d-limonene in male rats: Implications for risk assessment. Reg. Toxicol. Pharmacol. 13: 70-86.
21.
Frimmer M. (1987). What we have learned from phalloidin. Tox. Lett. 35: 169-182.
22.
Frimmer M. (1989). Uptake of foreign cyclopeptides by liver cells . In: Hepatic Transport of Organic Substances, E Petzinger, RKH Kinne , and H. Sies (eds). Springer-Verlag, Berlin, Heidelberg .
23.
Frimmer M. and Ziegler K. (1988). The transport of bile acids in liver cells. Biochem. Biophys. Acta947: 75-99.
24.
Gibson GG and Skett P. (1986). Introduction to Drug Metabolism. Chapman and Hall, London, New York.
25.
Gregus Z. and Klaassen CD (1986). Enterohepatic circulation of toxicants. In: Gastrointestinal Toxicity, K Rozman and O Hanninen (eds). Elsevier, Amsterdam, pp. 57-188.
26.
Guengerich FP (1993). The 1992 Bernard B Brodie award lecture. Bioactivation and detoxication of toxic and carcinogenic chemicals . Drug Metab. Dispos. 21: 1-5.
27.
Guengerich FP and Macdonald TL (1990). Mechanisms of cytochrome P-450 catalysis. FASEB J. 4: 2453-2459.
28.
Hedman A., Angelin B., Ardvisson A., Beck O., Dahlqvist R., Nilsson B., Olsson M., and Schenk-Gustafsson K. (1991). Digoxin-verapamil interaction: Reduction of biliary but not renal digoxin clearance in humans. Clin. Pharmacol. Ther. 49: 256-262.
29.
Hladky SB (1990). Pharmacokinetics. Manchester University Press, Manchester, New York.
30.
loannides C. and Parke DV (1987). Cytochromes P448-A unique family of enzymes involved in chemical toxicity and carcinogenesis . Biochem. Pharm. 36: 4197-4207.
31.
Jansen PLM and Oude Elferink RPJ (1993). Defective hepatic anion secretion in mutant TR- rats. In: Hepatic Transport and Bile Secretion: Physiology and Pathophysiology, N Tavoloni and PD Berk (eds). Raven Press, New York, pp. 721-731.
32.
Jerina DM, Michaud DP, Feldmann RJ, Armstrong RN, Vyas KP, Thakker DR, Yagi H., Thomas PE, Ryan DE, and Levin W. (1982). Stereochemical modeling of the catalytic site of cytochrome P450-c. In: Microsomes, Drug Oxidations and Drug Toxicity, R Sato and R Kato (eds). Japan Scientific Societies Press, Tokyo, pp. 195-203.
33.
Jerina DM, Sayer JM, Yagi H., van Bladeren PJ, Thakker DR, Levin W., Chang RL, Wood AW, and Conney AH (1985). Stereoselective metabolism of polycyclic aromatic hydrocarbons to carcinogenic metabolites. In: Microsomes and Dnig Oxidation, AR Boobis, J Caldwell, F DeMatteis, and CR Elcombe (eds). Taylor and Francis. Philadelphia, pp. 310-319.
34.
Jollow DJThorgeirsson SSPotter WFHashimoto M., and Mitchell JR (1974). Acetaminophen-induced hepatic necrosis. Pharmacology12: 251-271.
35.
Jones ALRoberts RC and Coughtrie MWH (1993). The human phenolsulfotransferase polymorphism is determined by the level of expression of the enzyme protein . Biochem. J. 296: 287-290.
36.
Kamimoto Y. , Gatmaitan Z.Hsu J. and Arias IM (1989). The function of Gp 170 multidrug resistance gene product. in rat liver canalicular membrane vesicles . J. Biol. Chem. 264: 11693-11698.
37.
Kitani K. (1988). Drugs and the ageing liver. Life Chem. Rep. 6: 143-230.
38.
Koymans LMH (1992). Computational chemistry in biotransformational and toxicological research: Mechanisms of oxidation by and active site structure of cytochromes P450. Free University of Amsterdam, Ph.D. Thesis.
39.
Koymans L., Donne-Op Den Kelder GMKoppele-Te JM and Vermeulen NPE (1993). Cytochrome P450 their active site structure and mechanism of oxidation. Drug Met. Rev. 25: 325-388.
40.
Koymans L., Vermeulen NPE, Van Acker SABE , te Koppele JM, Heykants JJD, Lavrijsen K., Meuldermans W., and Donne-Op Den Kelder GM (1992). A predictive model for substrates of cytochrome P450-debrisoquine 2D6. Chem. Res. Tox. 5: 211-219.
41.
Lehmann-McKeeman LD, Rivera-Torres MI, and Caudill D. (1990). Lysosomal degradation of α2u globulin and α2u globulin-xenobiotic conjugates. Toxicol. Appl. Pharmacol. 103: 539-548.
42.
Lewis DFV , loannides C., and Parke DV (1987). Structural requirements for substrates ofcytochrome P450 and cytochrome P448. Chem. Biol. Interact. 64: 39.
43.
Meijer DKF (1989). Transport and metabolism in the hepatobiliary system. In: Handbook of Physiology of the Gastrointestinal System, Vol. III, SG Schulz, JG Forte, and BB Rauner (eds). Oxford University Press, New York, pp. 717-758.
44.
Meijer DKF and Groothuis GMM (1991). Hepatic transport of drugs and proteins. In: Oxford Textbook of Clinical Hepatology, Vol. 1, N McIntyre, J Benhama, and H Bircher (eds). Oxford University Press, Oxford, pp. 40-78.
45.
Meijer DKF , Mol WEM , Muller M., and Kurz G. (1990). Carrier mediated transport in the hepatic distribution and elimination of drugs with special ref erences to the category of organic cations. J. Pharmaco. Biopharm . 18: 35-70.
46.
Meijer J. and Depierre JW (1988). Cytosolic epoxide hydrolase. Chem. Biol. Interact. 64: 207-249.
47.
Meister A. (1988). Glutathione. In: The Liver: Biology and Pathobiology, 2nd ed., IM Arias (ed). Raven Press, New York, pp. 401-417.
48.
Meyer UA, Skoda RC, Zanger UMHeim M. and Broly F. (1992). The genetic polymorphism of debrisoquine sparteine metabolism-Molecular mechanisms. In: Pharinacogenetics of Drug Metabolism, W Kalow. (ed). Pergamon Press, Oxford, pp. 609-623.
49.
Mulder GJCoughtrie MWH. and Burchell B. (1990). Glucuronidation. In: Conjugation Reactions in Drug Metabolism, GJ Mulder (ed). Taylor and Francis, London . pp. 51-106.
50.
Mulder GJ and Jakoby WB (1990). Sulfation. In: Conjugation Reactions in Drug Metabolism. GJ Mulder (ed). Taylor and Francis, London, pp. 107-162.
51.
Myrhe K., Rugstad HE, and Hansen T. (1982). Clinical pharmacokinetics of methyldopa. Clin. Pharmacokinet. 7: 221-223.
52.
Nebert DW, Nelson DR, Coon MJ, Estabrook RW, Feyereisen R., Fujii-Kuriyama Y., Gonzales FJ, Guengerich FP, Gunsalas IC, Johnson EF, Loper J., Sato R., Waterman MR, and Waxman DJ (1991). The P450 superfamily-Update on new sequences, gene mapping and recommended nomenclature. DNA Cell Biol. 10: 1-14.
53.
Nebert DW, Nelson DR, Coon MJ, Estabrook RW, Feyereisen R., Fujii-Kuriyama Y., Gonzales FJ, Guengerich FP, Gunsalas IC, Johnson EF, Loper JC, Sato R., Waterman MR, and Waxman DJ (1991). Correction. DNA Cell Biol. 10: 397-398.
54.
Newbeme JW (1975). Mouse hepatic neoplasia: Significance and extrapolation to man. In: Mouse Hepatic Neoplasia, WH Butler and PM Newbeme (eds). Elsevier Scientific, Amsterdam, pp. 165-177.
55.
Nishida T., Gatmaitan Z., Che M., and Arias IM (1991). Rat liver canalicular membrane vesicles contain an ATP-dependent bile acid transport system. Proc. Natl. Acad. Sci. USA88: 6590-6594.
56.
Nishida T., Gatmaitan Z., Roy-Chowdhury J., and Arias IM (1992). Two distinct mechanisms for bilirubin glucuronide transport by rat bile canalicular membrane vesicles. Demonstration of defective ATP-dependent transport in rats with inherited conjugated hyperbilirubinaemia . J. Clin. Invest. 90: 2130-2135.
57.
Nishida T., Hardenbrook C., Gatmaitan Z., and Arias IM (1992). ATP-dependent organic anion transport in normal and TR- rat liver canalicular membranes. Am. J. Physiol. 262: G629-G635.
58.
Oude Elferink RPJ , Ottenhof R., Radominska A., Hofmann A., Kuipers F., and Jansen PLM (1991). Inhibition of glutathione-conjugate secretion from isolated hepatocytes by dipolar bile acids and other organic anions. Biochem. J. 274: 281-286.
59.
Pearson RG and Songstad J. (1967). Application of the principles of hard and soft acids and bases to organic chemistry. J. Am. Chem. Soc. 89: 1827-1836.
60.
Peters WHM , Nauta H., and Jansen PLM (1985). The molecular masses and molecular structure of UDP glucuronyl transferase as determined by radiation inactivation analysis . In: Advances in Glucuronide Conjugation (Falk Symposium 40) , S Matem, KW Bock, and W Gerok (eds). MTP Press, Lancaster , pp. 235-244.
61.
Price-Evans DA (1993). N-acetyltransferase . In: Genetic Factors in Drug Therapy: Clinical and Molecular Pharmacogenetics . Cambridge University Press, Cambridge , pp. 211-285.
62.
Ryan RE and Levin W. (1990). Purification and characterization of hepatic microsomal cytochrome P-450. Pharmacol. Ther. 45: 153-239.
63.
Siedegard J. and De Pierre JW (1983). Microsomal epoxide hydrolase: Properties regulation and function. Biochim. Biophys. Acta695: 251-270.
64.
Sippel J., Suchy FJ, Ananthanarayanan M., and Perlmutter DH (1993). The rat liver ectoATPase is also a canalicular bile acid transport protein. J. Biol. Chem. 268: 2083-2091.
65.
Smith DA (1991). Species difference in metabolism and pharmacokinetics: Are we close to an understanding? Drug Metab. Rev. 23: 355-373.
66.
Smith DA and Jones BC (1992). Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. Biochem. Pharmacol . 44: 2089-2098.
67.
Smith RL (1973). The Excretory Function of Bile. The Elimination of Drugs and Toxic Substances in Bile. Chapman and Hall , London.
68.
Stott WT (1988). Chemically induced proliferation of peroxisomes-Implications for risk assessment. Reg. Toxicol. Pharmacol. 8: 125-129.
69.
Strobel G. and Wolff T. (1991). Molecular basis of drug metabolism interactions: A structural model for inhibitors of debrisoquine hydroxylase. Naunyn-Schmiedeberg's Arch. Pharmacol.343(suppl.): R8.
70.
Swenberg JA , Short B., Borghoff S., Strasser J., and Charbonneau M. (1989). The comparative pathobiology of α2u-globulin nephropathy. Toxicol. Appl. Pharmacol. 97: 35-46.
71.
Testa B. (1983). Non-enzymatic biotransformation. In: Biological Basis of Detoxication, J Caldwell and WB Jakoby (eds). Academic Press, London, New York, pp. 137-150.
72.
Timbrell JA (1993). Biotransformation of xenobiotics. In: General and Applied Toxicology, Vol. 1, B Ballantyne, T Marrs, and P Turner (eds). Macmillan Press, New York, pp. 89-121.
73.
Van Bladeren PJ, Breimer DD, Rotteral-Smijs GMT, de Jong RAW, Buijs W., Van der Ben A., and Mohn GR (1980). The role of glutathione conjugation in the mutagenicity of 1,2-bromoethane . Biochem. Pharmacol.29: 2975-2982.
74.
Watanabe T. , Miyauchi S., Sawada Y., Iga T., Hanano M., Inaba M., and Sugiyama Y. (1992). Kinetic analysis of hepatobiliary transport of vincristine in perfused rat liver: Possible role of P-glycoprotein in biliary excretion of vincristine . J. Hepatol. 16: 77-88.
75.
Weil A., Caldwell J., and Strolin-Benedetti M. (1988). The metabolism and disposition of fenofibrate in rat, guinea pig and dog. Drug Metab. Dispos . 16: 302-309.
76.
West IC (1990). What determines the specificity of the multi drug resistance pump? TrendsBiol. Sci. 15: 42-46.
77.
Wilce MCJ and Parker MW (1994). Structure and function of glutathione-S transferases . Biochem. Biophys. Acta1205: 1-18.
78.
Wilkinson GR (1987). Clearance concepts in pharmacology . Pharmacol. Rev. 39: 1-47.
